Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on 20/20 Biolabs, Inc. and keeping the price target at $5.00.

Meet Samuel – Your Personal Investing Prophet

• Start a conversation with TipRanks’ trusted, data-backed investment intelligence
• Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

Michael Okunewitch has given his Buy rating due to a combination of factors related to 20/20 Biolabs’ commercial momentum and growth outlook. Although first-quarter 2026 revenue declined to $0.4M because of order timing, he views this as temporary and expects a meaningful rebound as state-level screening contracts, including a $520K Maryland fire department program and a similar pending agreement, begin contributing more fully throughout 2026, with projected revenue growth of 44% in 2026 and faster acceleration in 2027.

He also highlights the strategic positioning of OneTest for Cancer as a low-cost, AI-enhanced, protein-based multi-cancer early detection test with competitive performance versus ctDNA offerings, supported by large studies and attractive at-home collection. In his view, the company’s expanding commercial channels, its new OneTest for Longevity platform as an additional upside lever, solid cash runway into 1Q27, and a clear path toward potential Medicare reimbursement in 2028 together justify maintaining a $5 price target and support a favorable risk-reward profile at current levels.

Okunewitch covers the Healthcare sector, focusing on stocks such as Ocugen, Kiora Pharmaceuticals, and Definium Therapeutics. According to TipRanks, Okunewitch has an average return of -2.1% and a 37.97% success rate on recommended stocks.

In another report released on May 8, Alliance Global Partners also maintained a Buy rating on the stock with a C$2.00 price target.